文献速递胸部CT

基于CT影像与治疗中游离DNA变化的局部晚期肺癌放射基因组学分析

Radiogenomic Analysis of Locally Advanced Lung Cancer Based on CT Imaging and Intratreatment Changes in Cell-Free DNA.
PubMed 文献 · Radiol Imaging Cancer · 2021-01-01

前瞻性初步研究纳入24例接受放化疗的III期肺癌患者,对CT影像组学特征进行无监督聚类,得到两个与ctDNA TP53突变及放化疗2周后cfDNA浓度变化相关的聚类;多个影像组学特征与总生存相关,提示影像表现可能与分子变化及预后相关。

要点

  • CT影像组学无监督聚类得到两个聚类,与ctDNA TP53突变(P = .03)及放化疗2周后cfDNA浓度变化(P = .02)相关。
  • 影像组学特征不相似度(HR = 0.56;P = .05)、联合熵(HR = 0.56;P = .04)、和熵(HR = 0.53;P = .02)、归一化逆差(HR = 1.77;P = .05)与总生存相关。
  • 结果提示异质性、低密度且无可检测ctDNA TP53突变的病变,与治疗早期cfDNA浓度升高及总体较好预后相关。

核心结论

  • 局部晚期肺癌的影像表现可能与治疗中的分子变化相关;异质性、低密度且无可检测ctDNA TP53突变的病变与治疗早期cfDNA浓度升高及总体较好预后相关。

研究设计与样本

  • 前瞻性初步研究(NCT00921739)纳入24例III期肺癌患者(中位年龄64岁,范围49-74岁),于2009年9月至2014年9月接受放化疗,分析CT影像组学、cfDNA液体活检与ctDNA二代测序。

关键影像表现/征象

  • 影像组学特征无监督聚类得到两个聚类,分别与ctDNA TP53突变(P = .03)和放化疗2周后cfDNA浓度变化(P = .02)相关。
  • 异质性、低密度且无可检测ctDNA TP53突变的病变,与治疗早期cfDNA浓度升高及总体较好预后相关。

诊断标准与关键数值

  • 影像组学特征不相似度与总生存相关(HR = 0.56;P = .05)。
  • 联合熵与总生存相关(HR = 0.56;P = .04)。
  • 和熵与总生存相关(HR = 0.53;P = .02)。
  • 归一化逆差与总生存相关(HR = 1.77;P = .05)。

局限性

  • 原文报告为初步研究(preliminary findings)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

The radiologic appearance of locally advanced lung cancer may be linked to molecular changes of the disease during treatment, but characteristics of this phenomenon are poorly understood. Radiomics, liquid biopsy of cell-free DNA (cfDNA), and next-generation sequencing of circulating tumor DNA (ctDNA) encode tumor-specific radiogenomic expression patterns that can be probed to study this problem. Preliminary findings are reported from a radiogenomic analysis of CT imaging, cfDNA, and ctDNA in 24 patients (median age, 64 years; range, 49-74 years) with stage III lung cancer undergoing chemoradiation on a prospective pilot study (NCT00921739) between September 2009 and September 2014. Unsupervised clustering of radiomic signatures resulted in two clusters that were associated with ctDNA TP53 mutations (P = .03) and changes in cfDNA concentration after 2 weeks of chemoradiation (P = .02). The radiomic features dissimilarity (hazard ratio [HR] = 0.56; P = .05), joint entropy (HR = 0.56; P = .04), sum entropy (HR = 0.53; P = .02), and normalized inverse difference (HR = 1.77; P = .05) were associated with overall survival. These results suggest heterogeneous and low-attenuating disease without a detectable ctDNA TP53 mutation was associated with early surges of cfDNA concentration in response to therapy and a generally better prognosis. Keywords: CT-Quantitative, Radiation Therapy, Lung, Computer Applications-3D, Oncology, Tumor Response, Outcomes Analysis Clinical trial registration no. NCT00921739 Supplemental material is available for this article. © RSNA, 2021.

来源:Radiol Imaging Cancer,查看原文。版权归原作者所有。

引用

  1. Lafata KJ, Corradetti MN, Gao J, et al. Radiogenomic Analysis of Locally Advanced Lung Cancer Based on CT Imaging and Intratreatment Changes in Cell-Free DNA. Radiol Imaging Cancer. 2021. PMID: 34114913. doi:10.1148/rycan.2021200157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。